GFAP and COVID-19: While traditionally considered a marker of astrogliosis, blood GFAP levels have been suggested to reflect disruption of the blood–brain barrier in acute CNS injury [27] and in highly inflammatory conditions, such as coronavirus disease 2019 (COVID-19) [28].